- Home
- KTTA vs GLMD Comparison
KTTA vs GLMD Comparison
Compare KTTA & GLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KTTA
- GLMD
- Stock Information
- Founded
- KTTA 2020
- GLMD 2000
- Country
- KTTA United States
- GLMD Israel
- Employees
- KTTA N/A
- GLMD N/A
- Industry
- KTTA Biotechnology: Pharmaceutical Preparations
- GLMD Biotechnology: Pharmaceutical Preparations
- Sector
- KTTA Health Care
- GLMD Health Care
- Exchange
- KTTA Nasdaq
- GLMD Nasdaq
- Market Cap
- KTTA 2.8M
- GLMD 3.0M
- IPO Year
- KTTA 2021
- GLMD 2014
- Fundamental
- Price
- KTTA $0.89
- GLMD $1.51
- Analyst Decision
- KTTA
- GLMD Hold
- Analyst Count
- KTTA 0
- GLMD 1
- Target Price
- KTTA N/A
- GLMD N/A
- AVG Volume (30 Days)
- KTTA 2.3M
- GLMD 255.6K
- Earning Date
- KTTA 05-15-2025
- GLMD 06-17-2025
- Dividend Yield
- KTTA N/A
- GLMD N/A
- EPS Growth
- KTTA N/A
- GLMD N/A
- EPS
- KTTA N/A
- GLMD N/A
- Revenue
- KTTA N/A
- GLMD N/A
- Revenue This Year
- KTTA N/A
- GLMD N/A
- Revenue Next Year
- KTTA N/A
- GLMD N/A
- P/E Ratio
- KTTA N/A
- GLMD N/A
- Revenue Growth
- KTTA N/A
- GLMD N/A
- 52 Week Low
- KTTA $0.79
- GLMD $1.15
- 52 Week High
- KTTA $7.50
- GLMD $23.80
- Technical
- Relative Strength Index (RSI)
- KTTA 38.94
- GLMD 56.28
- Support Level
- KTTA $0.87
- GLMD $1.36
- Resistance Level
- KTTA $0.95
- GLMD $1.60
- Average True Range (ATR)
- KTTA 0.07
- GLMD 0.09
- MACD
- KTTA 0.01
- GLMD 0.03
- Stochastic Oscillator
- KTTA 40.41
- GLMD 79.07
About KTTA Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).
About GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.